Literature DB >> 15795534

Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation.

David L McGlasson1, Daniel A Kaczor, Richard A Krasuski, Charles L Campbell, Maria R Kostur, Joseph T Adinaro.   

Abstract

The purpose of this study was to determine whether the anti-activated factor X (anti-FXa) assay is less affected by pre-analytical variables in monitoring patients on unfractionated heparin (UFH) and low molecular weight heparin (LMWH) than the activated partial thromboplastin time (aPTT). Forty-six subjects receiving either enoxaparin (LMWH) or UFH were randomly selected. Each study subject had six vacutainer tubes (3.8% sodium citrate, 3.2% sodium citrate) drawn by an atraumatic venipuncture. One tube from each set had a blood to anticoagulant ratio of 9: 1. The other tube had an intentional "short-draw" of approximately 6: 1 blood to anticoagulant ratio. All specimens had an aPTT and a chromogenic anti-FXa assay performed on each specimen regardless of heparin type. The aPTT assay mean with the 3.8% sodium citrate tube short-draw tube was statistically different from the other aPTT assays (P = 0.06). However, all six of the mean anti-FXa assays for the UFH and LMWH heparin subjects were not statistically or clinically different (analysis of variance, P = 0.9878 for UFH and P = 0.9060 for LMWH). The intentional short-draw tube did not affect the anti-FXa assay regardless of the anticoagulant. The anti-FXa assay appears to be a better method for monitoring heparin subjects than the aPTT due to the lack of effect of pre-analytical variables.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15795534     DOI: 10.1097/01.mbc.0000164424.90545.6e

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  5 in total

1.  Is citrate theophylline adenosine dipyridamole (CTAD) better than citrate to survey unfractionated heparin treatment? Has delayed centrifugation a real impact on this survey?

Authors:  Paul Billoir; Thomas Clavier; Arnaud Guilbert; Virginie Barbay; Marie Hélène Chrétien; Marielle Fresel; Caroline Abriou; Christophe Girault; Véronique Le Cam Duchez
Journal:  J Thromb Thrombolysis       Date:  2019-08       Impact factor: 2.300

2.  Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability.

Authors:  Job Harenberg; Roland Krämer; Christina Giese; Svetlana Marx; Christel Weiss; Martin Wehling
Journal:  J Thromb Thrombolysis       Date:  2011-10       Impact factor: 2.300

3.  Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy.

Authors:  Jung-Hyun Byun; In-Seok Jang; Jong Woo Kim; Eun-Ha Koh
Journal:  Blood Res       Date:  2016-09-23

4.  Evaluation of Anti-Activated Factor X Activity and Activated Partial Thromboplastin Time Relations and Their Association with Bleeding and Thrombosis during Veno-Arterial ECMO Support: A Retrospective Study.

Authors:  Mouhamed Djahoum Moussa; Jérôme Soquet; Antoine Lamer; Julien Labreuche; Guillaume Gantois; Annabelle Dupont; Osama Abou-Arab; Natacha Rousse; Vincent Liu; Caroline Brandt; Valentin Foulon; Guillaume Leroy; Guillaume Schurtz; Emmanuel Jeanpierre; Alain Duhamel; Sophie Susen; André Vincentelli; Emmanuel Robin
Journal:  J Clin Med       Date:  2021-05-17       Impact factor: 4.241

5.  A feasibility study prior to an international multicentre paediatric study to assess pharmacokinetic/pharmacodynamic sampling and sample preparation procedures, logistics and bioanalysis.

Authors:  Agnes Maria Ciplea; Stephanie Laeer; Bjoern Bengt Burckhardt
Journal:  Contemp Clin Trials Commun       Date:  2018-08-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.